GLP-1 Injection Frequency: Dosing Schedules Explained

Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery | Last updated: July 10, 2026

Key Takeaways

• GLP-1 receptor agonists follow dosing schedules based on each medication’s half-life. Most modern agents use once-weekly subcutaneous injections to maintain steady therapeutic levels.
• Approved schedules differ by drug. Semaglutide, tirzepatide, and dulaglutide are once weekly, liraglutide is daily, and exenatide is twice daily. Changing these intervals without clinical guidance can increase side-effect risk.
• Missed-dose rules are medication-specific and depend on how much time remains before the next injection. Patients should never double-dose to make up for a missed injection.
• Dose escalation follows structured titration schedules, usually every 4 weeks. This gradual increase helps limit gastrointestinal side effects while building toward an effective maintenance dose.
• For personalized GLP-1 dosing guidance and a medically supervised protocol, schedule a consultation to review your dosing options at Mirror Plastic Surgery.

Approved GLP-1 Dosing at a Glance

This overview highlights how often the most widely used GLP-1 receptor agonists are injected, why that interval is chosen, and the current maximum weight-management dose as of 2026. Notice how half-life shapes dosing frequency. Longer half-lives support once-weekly injections, while shorter half-lives require daily or twice-daily dosing to maintain therapeutic levels.

Medication	Approved Frequency	Half-Life Rationale	2026 Max Weight-Management Dose
Semaglutide (Wegovy / Ozempic)	Once weekly (subcutaneous injection)	~7-day half-life, drug reduces by half after 7 days and takes ~5 weeks to fully clear	7.2 mg once weekly (Wegovy HD, FDA-approved March 19, 2026)
Tirzepatide (Zepbound / Mounjaro)	Once weekly (subcutaneous injection)	Extended half-life supports once-weekly dosing. Dose escalation occurs every 4 weeks starting at 2.5 mg.	15 mg once weekly
Dulaglutide (Trulicity)	Once weekly (subcutaneous injection)	Long half-life permits weekly dosing. A 72-hour missed-dose window reflects sustained plasma levels.	4.5 mg once weekly (type 2 diabetes indication; not separately approved for weight management)
Liraglutide (Victoza / Saxenda)	Once daily (subcutaneous injection)	Shorter half-life (~13 hours) requires daily dosing to maintain therapeutic plasma concentrations.	3.0 mg once daily (Saxenda)
Exenatide (Byetta)	Twice daily (subcutaneous injection)	Short half-life (~2.4 hours) requires twice-daily administration. Doses must be separated by at least 6 hours and injected within 1 hour before breakfast and dinner.	10 mcg twice daily (diabetes indication only)

Review your current regimen with Ellie to explore whether a personalized protocol better fits your goals.

Ozempic Injection Timing: 5 Days vs 7 Days

Ozempic (semaglutide) follows a once-weekly subcutaneous schedule, given on the same day each week at any time of day, with or without meals. The approved interval is 7 days, not 5. Injecting every 5 days compresses the schedule, raises plasma concentrations above the intended range, and increases the chance of gastrointestinal side effects without added clinical benefit.

Adjusting the injection day is possible in some cases, such as moving from Monday to Wednesday. The gap between two consecutive doses must stay at or above 2 days (48 hours), and any change in injection day should be cleared with a clinician. The 7-day interval reflects semaglutide’s pharmacokinetic profile, where drug concentration in the body falls by half after about 7 days.

Tirzepatide Frequency: Why Every 5 Days Is Not Recommended

Tirzepatide (Zepbound for weight management, Mounjaro for type 2 diabetes) is approved as a once-weekly subcutaneous injection. Shortening the interval to every 5 days falls outside prescribing guidelines and is not advised. The standard escalation starts at 2.5 mg once weekly, with 2.5 mg increases every 4 weeks, reaching a maintenance dose between 5 mg and 15 mg. Compressing the schedule does not speed weight loss and adds unnecessary risk of nausea, vomiting, and other adverse effects.

Consequences of Injecting Semaglutide Twice in One Week

Injecting semaglutide twice in one week, whether on purpose or by mistake, effectively doubles the weekly dose. Prescribing guidelines state that two doses must never be taken at once to compensate for a missed dose, and the same safety principle applies to any unsupervised double-dosing. Excess semaglutide exposure raises the risk of severe nausea, vomiting, diarrhea, and hypoglycemia in patients who also use insulin or sulfonylureas. Patients should not split or alter weekly doses unless their healthcare provider gives specific instructions.

GLP-1 Missed-Dose Protocol

Each GLP-1 medication has a specific missed-dose window based on its half-life. These rules reflect current prescribing information and support safer decisions, but they do not replace individualized clinical guidance.

• For once-weekly injectable semaglutide (Ozempic or Wegovy): Take the missed dose as soon as possible if more than 2 days (48 hours) remain before the next scheduled dose. If fewer than 2 days remain, skip the missed dose and return to the regular weekly schedule. For Ozempic specifically, the missed dose may be taken within 5 days of the scheduled day; beyond 5 days, skip it.
• For once-weekly tirzepatide (Mounjaro or Zepbound): Take the missed dose if at least 3 days (72 hours) remain before the next scheduled dose; otherwise, skip it.
• For once-weekly dulaglutide (Trulicity): Take the missed dose if at least 3 days (72 hours) remain; otherwise, skip it.
• For once-daily liraglutide (Victoza or Saxenda): Skip the missed dose and administer the next dose at the usual time. Never inject more than one dose within 24 hours. If three or more consecutive doses are missed, restart at the lowest 0.6 mg dose and increase weekly.
• For twice-daily exenatide (Byetta): Skip the missed dose, give the next dose at the usual time, keep doses at least 6 hours apart, and inject within 1 hour before breakfast and dinner.

Missing multiple consecutive doses may require re-titration from a lower dose to reduce serious adverse effects when restarting a higher therapeutic dose. Patients who miss two or more consecutive once-weekly doses should contact their prescriber, as a temporary dosage reduction may be required. While missed doses call for careful protocols, planned dose increases follow their own structured approach.

When Should GLP-1 Dose Be Increased?

Dose escalation for GLP-1 therapies follows a structured titration schedule that balances symptom relief with tolerability. Wegovy (semaglutide) for weight loss usually starts at 0.25 mg once weekly, then increases every 4 weeks through 0.5 mg, 1.0 mg, and 1.7 mg before reaching a 2.4 mg maintenance dose.

A clinician first confirms that the initial 4-week adjustment period at the current dose is complete and that early side effects, such as nausea, have settled. Once that baseline tolerability is clear, a dose increase becomes reasonable if weight loss has plateaued despite adherence to diet and exercise or if hunger and food noise return at the current dose. These outcome changes suggest that the therapeutic effect has weakened and that a higher dose may be needed.

Dose increases are never self-directed. The American Diabetes Association’s 2026 Standards of Care highlight shared decision-making that considers cost, access, tolerability, adverse effects, and individual preferences when selecting and dosing obesity medications.

Beyond the approved GLP-1 agents already discussed, newer investigational compounds are expanding metabolic treatment options. Some of these agents target multiple receptor pathways at once, which may change future dosing patterns and tolerability profiles.

GLP-3R Retatrutide: An Emerging Weekly Triple Agonist

Retatrutide, often called a GLP-3R agent because of its triple-receptor mechanism, is a once-weekly subcutaneous injection that targets GLP-1, GIP, and glucagon receptors simultaneously. This profile contrasts with single-agonist semaglutide and dual-agonist tirzepatide. Retatrutide is in Phase 3 development and has not yet received FDA approval for general use.

Key distinctions from approved GLP-1 agents include both efficacy and tolerability. The 4 mg dose achieved 19.0% mean weight loss at 80 weeks with only a single escalation step¹, and the highest dose produced 28.3% weight loss in Phase 3 TRIUMPH-1 trials¹. Retatrutide starts at 2 mg once weekly and escalates every four weeks to 4 mg, 8 mg, then 12 mg, with the 4 mg level linked to the 19.0% weight loss noted above.

Gastrointestinal side effects such as nausea, diarrhea, vomiting, and constipation remain the most common adverse events, and they appear more often at higher doses. At the 12 mg dose, 20.9% of participants experienced dysesthesia, described as burning, tingling, or pins-and-needles sensations. These symptoms were usually mild to moderate and often improved during treatment, but they contributed to higher discontinuation rates at the top dose compared with approved agents.

The broader potential of GLP-3R agents includes effects on insulin resistance, cardiovascular risk factors, and overall metabolic health beyond weight loss alone. Because retatrutide remains investigational, any compounded GLP-3R formulation differs from the product studied in trials and should only be considered under direct medical supervision with clear disclosure of its regulatory status.

Key Terminology for GLP-1 and GLP-3R Therapy

• GLP-1 receptor agonist: A class of medications that bind to and activate glucagon-like peptide-1 receptors, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite.
• Half-life: The time required for the concentration of a drug in the body to fall by 50 percent. This value directly shapes how often a medication must be given to maintain therapeutic levels.
• Titration: The gradual increase of a drug dose over a defined schedule to improve tolerability and limit side effects while reaching a therapeutic target.
• Maintenance dose: The dose that maintains the desired clinical effect after the titration phase is complete.
• Re-titration: Restarting at a lower dose after missed doses or a treatment break to reduce the risk of adverse effects when therapy resumes.
• Triple agonist (GLP-3R): A compound that activates GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors at the same time, creating a broader metabolic effect than single or dual agonists.
• Subcutaneous injection: Administration of a medication into the fatty tissue just beneath the skin, usually in the abdomen, thigh, or upper arm.

Understanding these terms supports informed decisions, yet applying them to your health profile requires clinical expertise and a tailored protocol.

Clinical Workflow at Mirror Plastic Surgery

Ellie Pranckevicius, FNP-BC, leads peptide and GLP-1-adjacent protocols at Mirror Plastic Surgery. Her background includes four years in the Neuroscience ICU at Tampa General Hospital, aesthetics licensure, advanced nursing degrees (BSN and MSN from the University of South Florida), and a premedical undergraduate degree from Boston University. This blend of critical-care physiology and aesthetic training supports protocol design that is clinically rigorous and individually tailored.

The clinical workflow at Mirror Plastic Surgery follows a structured sequence. It begins with a comprehensive 30–60 minute evaluation that reviews medical history, current medications, metabolic health goals, and any prior GLP-1 experience. That consultation guides which lab panels are needed, including thyroid, liver, kidney, diabetes markers, and hormone levels, to identify root causes and contraindications before any protocol starts.

Once lab results are available, Ellie designs a personalized protocol around those findings, the patient’s health profile, and their goals. Peptide sourcing is limited to providers with documented batch testing. Patients then receive ongoing remote support through direct text access to Ellie for questions, dose-timing concerns, side-effect management, and refill coordination, whether they are local to St. Petersburg or Tampa or working with the practice remotely across the United States.

Start your medically supervised evaluation to receive a protocol built around your specific lab results and health history.

2026 GLP-1 and Peptide Landscape: What Changed for Dosing

The GLP-1 and related peptide space has expanded rapidly in 2025–2026, creating new dosing options that affect how patients and clinicians think about injection frequency and protocol design.

• On March 19, 2026, the FDA approved Wegovy HD (semaglutide 7.2 mg) for once-weekly subcutaneous administration, demonstrating 20.7% mean weight loss at 72 weeks¹. This approval keeps the familiar weekly schedule while raising the dose ceiling.
• On April 1, 2026, the FDA approved orforglipron (Foundayo), a once-daily oral nonpeptide GLP-1, available in multiple tablet strengths with no food or water restrictions. This option removes injection timing from the equation and shifts adherence to a daily pill routine.
• The American College of Physicians 2026 guidelines designate semaglutide and tirzepatide as first-line pharmacologic treatments for nonpregnant adults with obesity (BMI ≥30 kg/m²), reinforcing weekly GLP-1 schedules as standard care for many patients.
• Longer-acting injectables moving toward monthly dosing intervals are in development, with Amgen’s MariTide positioned as a once-monthly option. These agents may further reduce injection frequency once approved.
• January 2026 data published in the British Medical Journal showed that patients who discontinue GLP-1 weight-loss injections regain weight four times faster than those who stop conventional dieting and exercise¹. This finding supports long-term continuation of therapy when appropriate.

Important Considerations for GLP-1 Use

• Not all GLP-1 medications use weekly injections. Liraglutide requires daily dosing, and exenatide requires twice-daily dosing because of their shorter half-lives.
• Injection frequency should not be changed casually. Compressing or extending intervals without clinical guidance disrupts plasma drug levels and raises adverse-event risk.
• Compounded versions of GLP-1 medications are not equivalent to FDA-approved brand-name products and involve different quality, purity, and dosing considerations.
• The American Diabetes Association and the American College of Cardiology recommend long-term continuation of GLP-1 receptor agonists for most patients to sustain weight loss and manage related conditions.
• Rotating injection sites among the abdomen, thigh, and upper arm at each administration reduces local tissue reactions.

Beyond these protocol rules, patients also face real-world challenges and physiological risks during GLP-1 therapy.

Risks, Limitations, and Common Challenges

• Gastrointestinal side effects: Nausea, vomiting, diarrhea, and constipation are the most common adverse effects across GLP-1 classes and tend to increase with higher doses.
• Muscle loss: Rapid weight loss on GLP-1 therapies can include loss of lean muscle mass. Structured resistance training and adequate protein intake are standard strategies to protect muscle.
• Adherence challenges: A 2024 study found that real-world persistence and adherence issues with GLP-1 receptor agonists are common among obese adults without diabetes.
• Weight regain upon discontinuation: People who stop GLP-1 medications typically regain up to two-thirds of the weight lost within one year¹.
• Retatrutide-specific tolerability: William Blair analysts noted that retatrutide’s tolerability profile could limit its use to patients at the higher end of the BMI spectrum.
• Supply and access: Pharmacy shortages and logistical gaps remain common. UCLA recommends seeking a doctor’s advice if you cannot access GLP-1 injection pens after 14 days.

Frequently Asked Questions

How often should GLP-1 injections be administered?

The correct frequency depends on the specific medication. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) follow once-weekly schedules, as shown in the dosing table above. Dulaglutide (Trulicity) is also once weekly. Liraglutide (Victoza, Saxenda) is once daily, and exenatide (Byetta) is twice daily. These intervals reflect each drug’s half-life and should not be compressed or extended without clinical oversight.

What should I do if I miss a GLP-1 injection?

The correct action depends on which medication you use and how much time has passed. Detailed missed-dose windows for each drug appear in the “GLP-1 Missed-Dose Protocol” section above. As a general rule for once-weekly agents, if you are within the final 2–3 days before your next dose, skip the missed dose entirely. For daily liraglutide, skip the missed dose and resume the next day. Never double-dose to make up for a missed injection. If you have missed multiple consecutive doses, contact your prescriber before restarting, since re-titration from a lower dose may be needed.

What is GLP-3R and how does it differ from standard GLP-1 medications?

GLP-3R refers to retatrutide, a triple-receptor agonist that activates GLP-1, GIP, and glucagon receptors at the same time. Standard GLP-1 agents such as semaglutide act only on the GLP-1 receptor, while tirzepatide targets GLP-1 and GIP. The triple-agonist mechanism of retatrutide has produced greater weight loss in clinical trials, up to 28.3 percent in Phase 3 data, but also a higher rate of adverse events at the top doses compared with tirzepatide. Retatrutide uses a once-weekly injection schedule similar to approved weekly GLP-1 agents. It remains investigational and has not yet received FDA approval. Any compounded GLP-3R formulation is not equivalent to the investigational drug used in trials.

When is a GLP-1 dose increase appropriate?

Dose increases follow a structured titration schedule, usually every 4 weeks. A clinician may advance the dose once the initial adjustment period at the current level is complete and early side effects have improved. A plateau in weight loss despite lifestyle adherence or the return of hunger and food noise can also prompt a dose review. Dose escalation always occurs in the context of a patient’s full health profile, lab results, and tolerability history, not as a self-directed change.

Why does medically supervised GLP-1 therapy matter compared with online sources?

Unsupervised use of GLP-1 or peptide therapies from unregulated online sources carries real risks. These products often lack third-party quality testing, have unknown active ingredient concentrations, and come without screening for contraindications or guidance on dose timing and missed-dose management. Medically supervised care includes a thorough health history review, targeted lab panels, individualized protocol design, and ongoing clinical support. This structure becomes especially important with compounded formulations, which are not FDA-approved and must be sourced from providers with documented batch testing to confirm purity and accurate dosing.

Decisions about GLP-1 injection frequency, dose escalation, and missed-dose management rely on each patient’s pharmacokinetic response, health history, and treatment goals. The information above reflects current prescribing guidelines and 2026 clinical data, yet it does not replace individualized medical advice. Get your lab-informed protocol and concierge support at Mirror Plastic Surgery to navigate these therapies safely and effectively.

---